Psychiatry AdvisorCannabinoid-Based Therapies May Effectively Treat Symptoms of Alzheimer Disease

🧠 Mental Health / Behavioral Sensitivity

Behavioral and psychological symptoms remain a major management challenge in moderate to severe Alzheimer disease. A systematic review and meta-analysis of seven studies found cannabinoid-based therapies were associated with reductions in agitation and overall neuropsychiatric symptom burden compared with placebo.

Clinical Considerations

• Neuropsychiatric Inventory total scores were lower with cannabinoid therapy versus placebo across four studies.
• Agitation measures improved, including lower CMAI-SF scores and NPI agitation/aggression domain scores.
• MMSE findings did not demonstrate consistent cognitive benefit, suggesting symptom control rather than cognitive improvement.
• Somnolence was the principal adverse event, occurring more than twice as often in cannabinoid-treated patients.

Practice Applications

• Recognize agitation reduction as the primary signal emerging from current cannabinoid evidence.
• Interpret findings within the context of small studies and heterogeneous cannabinoid formulations.
• Monitor sedation risk when evaluating cannabinoid-based treatment approaches.
• Consider current evidence as hypothesis-generating pending larger randomized trials.